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Abstract
Background: Zinc supplementation can modulate immunity through inhibition of NF-B, a transcription factor
that controls many immune response genes. Thus, we sought to examine the mechanism by which zinc
supplementation tempers the response to a common allergen and determine its effect on allergic airway
inflammation.
Methods: Mice were injected with zinc gluconate prior to German cockroach (GC) feces (frass) exposure and
airway inflammation was assessed. Primary bone marrow-derived neutrophils and DMSO-differentiated HL-60 cells
were used to assess the role of zinc gluconate on tumor necrosis factor (TNF)a expression. NF-B:DNA binding and
IKK activity were assessed by EMSA and in vitro kinase assay. Protein levels of A20, RIP1 and TRAF6 were assessed
by Western blot analysis. Establishment of allergic airway inflammation with GC frass was followed by
administration of zinc gluconate. Airway hyperresponsiveness, serum IgE levels, eosinophilia and Th2 cytokine
production were assessed.
Results: Administration of zinc gluconate prior to allergen exposure resulted in significantly decreased neutrophil
infiltration and TNFa cytokine release into the airways. This correlated with decreased NF-B activity in the whole
lung. Treatment with zinc gluconate significantly decreased GC frass-mediated TNFa production from bone-
marrow derived neutrophils and HL-60 cells. We confirmed zinc-mediated decreases in NF-B:DNA binding and IKK
activity in HL-60 cells. A20, a natural inhibitor of NF-B and a zinc-fingered protein, is a potential target of zinc.
Zinc treatment did not alter A20 levels in the short term, but resulted in the degradation of RIP1, an important
upstream activator of IKK. TRAF6 protein levels were unaffected. To determine the application for zinc as a
therapeutic for asthma, we administered zinc following the establishment of allergic airway inflammation in a
murine model. Zinc supplementation decreased airway hyperresponsiveness and serum IgE levels, but had no
effect on Th2 cytokine expression.
Conclusions: This report suggests that the mechanism by which zinc supplementation alters NF-B activity is via
the alteration of A20 activity. In addition, this study provides evidence that supplementation of zinc to asthmatics
may alter airway reactivity and serum IgE levels, suggesting zinc supplementation as a potential treatment for
asthmatics.
Introduction
Zinc is an essential trace element acquired by dietary
means. It plays a central role in modulating the immune
system and is essential for cellular function in the
immune response as well as acting as an antioxidant [1].
The syndrome of zinc deficiency in humans is charac-
terized by susceptibility to infections and in a mouse
model of polymicrobial sepsis, zinc deficiency increased
organ damage and mortality [2]. Zinc is known to mod-
ulate the immune system via the NF-B pathway, a ubi-
quitous transcription factor that controls many immune
response genes including cytoplasmic cytokines, decreas-
ing the inflammatory response; however the mechanism
by which this occurs is currently unclear [3]. A20 is an
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important regulator protein of NF-B, acting as an inhi-
bitor to shut down its activation. Its transcription is
induced by NF-B, suggesting a negative feedback loop
to temper inflammation [4]. A20 is also a seven zinc fin-
ger protein that functions as an ubiquitin-editing
enzyme downstream in the TNFR (tumor necrosis factor
receptor 1) and TLR (toll-like receptor) pathways
toward NF-B activation. In order to inhibit NF-B acti-
vation, A20 alters the ubiquitination of receptor-inter-
acting protein 1(RIP1), a protein crucial for the
activation of IKK, to target it for degradation and also
inactivates TNF receptor-associated factor 6 (TRAF6) by
inhibiting its polyubiquitination [5]. Thus A20, as a cri-
tical player in suppressing NF-B activation [6] and as a
zinc-containing protein, became a potential target for
the location of zinc’s effect in immune modulation.
Because of its immune modulating effects, zinc has
also gained considerable interest with respect to airway
inflammation and asthma. Many articles have documen-
ted a relative zinc deficiency in asthmatics, or patients
who wheeze, implicating a loss of inflammatory modula-
tion as a potential initiator of symptoms. Serum zinc
levels in asthmatics have been found to be lower when
compared to non-asthmatics [7,8]; hair zinc levels were
lower in wheezy infants when compared to healthy con-
trols [9]; and finally, zinc levels in the sputum of asth-
matics were significantly lower than in healthy subjects
and were associated with increased frequency of wheeze,
severity of asthma, and worse lung function [10]. With
this data in mind, and with the ability to supplement
zinc in an already established model of airway inflam-
mation, we also sought to examine zinc’s effect on air-
way inflammation and reactivity with the hope that it
may be considered as a therapeutic medication in rele-
vant patients.
In these studies, we were able to reaffirm zinc’s action
as an anti-inflammatory agent via inhibition of the NF-
B pathway and present evidence that zinc alters the
activity of inhibitory protein A20. In addition, our data
support a role for zinc supplementation in decreasing
airway reactivity and serum IgE levels in a murine
model of experimental allergic airway inflammation.
Materials and methods
GC frass
Fecal remnants (frass) were collected from German
cockroaches (Blattella germanica) and reconstituted as
previously described in endotoxin-free PBS [11]. The
frass preparation was frozen in aliquots and the same
batch was used throughout the experiments.
Animals and GC frass exposure
Six week old female BALB/c mice were obtained from
Jackson Laboratory (Bar Harbor, ME). Administration of
zinc gluconate (0.1, 1 and 10 mg/kg) was performed by
intraperitoneal (i.p.) injection for 3 days. On the third
day, mice (n = 6 mice/group) were anesthetized with
ketamine (45 mg/kg)/xylazine (8 mg/kg) and exposed to
PBS (40 μl) or GC frass (40 μg/40 μl) via intratracheal
instillation [12]. Mice were given a lethal dose of sodium
pentobarbital 24 h later and bronchoalveolar lavage
(BAL) fluid was isolated (Figure 1A). These studies were
approved by the Cincinnati Children’s Hospital Medical
Center Institutional Animal Care and Use Committee.
Assessment of airway inflammation
Lungs were lavaged thoroughly with 1 ml of Hanks
balanced salt solution (HBSS) without calcium or mag-
nesium. The bronchoalveolar lavage fluid (BAL) was
centrifuged (1,800 rpm for 10 min); the supernatant was
removed for TNFa analysis by ELISA (R&D Systems,
Minneapolis, MN) and immediately stored at -80°C.
Total cell numbers were counted on a hemocytometer.
Smears of BAL cells prepared with a Cytospin II (Shan-
don Thermo, Waltham, MA) were stained with Diff-
Quick (Thermo Electron Corporation, Pittsburg, PA)
solution for differential cell counting.
Primary mouse bone marrow-derive neutrophils
Bone marrow from femurs and tibias was isolated,
rinsed and red blood cells were lysed. Resuspended cells
were layered onto a three step Percoll gradient (52%,
64%, 72%) and centrifuged (1,000 rpm for 30 min at
Figure 1 Mouse treatment protocols. A. Zinc supplementation
followed by GC frass exposure. B. Allergen challenge with GC frass
followed by zinc supplementation.
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RT). The bottom layer (64%-72%) containing neutro-
phils was collected, counted and plated as previously
described [13]. Cells (1 × 106) were cultured in MEM
medium supplemented with 10% fetal bovine serum 50
μg/ml streptomycin, 2 U/mL penicillin, and 2 mM L-
glutamine for treatment.
Cell culture
HL-60 promyelocytic leukemia cells (ATCC, Manassas,
VA) were cultured in MEM medium and were differen-
tiated in the presence of 1% DMSO for 3 days. Cells
were centrifuged, washed and deprived of serum for 6 h.
For all cell culture experiments, cells were treated with
the following concentrations of GC frass (1 μg/ml), LPS
(1 μg/ml; from E. Coli 055:B5, Sigma Chemical Corp, St.
Louis, MO) in the presence or absence of zinc gluconate
(1 μM; Spectrum Chemicals, New Brunswick, NJ) and
the zinc ionophore, pyrithione (10 μM; 2-mercapopyri-
dine N-oxide, Sigma Chemical Corp). In all cases, zinc
was added in the presence of pyrithione, except where
noted. Lactase dehydrogenase (LDH) cytotoxicity assay
kit (US Biological, Marblehead MA) was performed on
cell supernatants to determine if zinc gluconate and/or
pyrithione treatment resulted in cell death.
Assessment of TNFa production
Following treatment, cell culture media was clarified by
centrifugation (10,000 g × 10 min) and immediately
stored at -80°C. The fluid was analyzed for TNFa using
an ELISA kit from R&D Systems (Minneapolis, MN).
Electrophoretic mobility shift assay (EMSA)
HL-60 cells were treated as described for 1 h. Cells were
harvested and nuclear proteins isolated as previously
described [14]. All nuclear extraction procedures were
performed on ice with ice-cold reagents. Protein con-
centrations were determined by Bradford assay (Bio-
Rad, Hercules, CA) and stored at -70°C until use. The
probe was labeled with [g-32P]ATP using T4 polynucleo-
tide kinase (Invitrogen, Carlsbad, CA) and purified in
MicroBiospin chromatography column. The gel was run
using 10 μg of nuclear protein as previously described
[14]. An oligonucleotide probe encoding the consensus
sequence of NF-B was purchased from Santa Cruz
(Santa Cruz, CA). Non-radioactive specific and non-spe-
cific probes were added at 5× the concentration of the
radiolabeled probe. Gels were transferred to Whatman 3
M paper, dried under a vacuum at 80°C for 1 h, and
exposed using a Phosphoimager.
IKK phosphorylation
HL-60 cells were treated as described above for 1 h.
Cellular lysate was harvested, and IKK was immunopre-
cipitated using an IKKg antibody bound to protein G
beads. The beads were pulled down and incubated with
GST-IBa and 32P-ATP. The samples were isolated by
gel electrophoresis and exposed to film. An IKKg (Santa
Cruz, Santa Cruz, CA) Western blot was performed to
confirm equal immunoprecipitation.
Western blot analysis
Following treatment, whole cell lysates were isolated and
separated on an 8-16% Tris-glycine gel (Invitrogen,
Carlsbad, CA). A20 (eBioscience, San Diego, CA), RIP1
(R&D Systems, Minneapolis, MN), TRAF6 and b-actin
(both from Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) were detected by Western Blot analysis.
Murine model of allergic airway inflammation
For airway administration of allergen, mice were given
three intratracheal inhalation challenges of PBS (40 μl)
or GC frass (40 μg/40 μl) on days 0, 7, and 14 (n = 6
mice/group). On days 14, 15, and 16, mice were injected
i.p. with either PBS or zinc gluconate (10 mg/kg). Mice
were harvested on day 17 for allergic airway responses
(Figure 1B).
Airway hyperresponsiveness measurements
Allergen-induced airway hyperresponsiveness (AHR) was
determined as we have previously described [15]. Briefly,
mice were anesthetized 72 hours after the last GC frass
exposure, intubated and ventilated at a rate of 120
breaths per minute with a constant tidal volume of air
(0.2 ml), and paralyzed with decamethonium bromide
(25 mg/kg). After establishment of a stable airway pres-
sure, 25 μg/kg weight of acetylcholine was injected i.v.
and dynamic airway pressure (airway pressure time index
[APTI] in cm-H2O × sec
-1) was followed for 5 minutes.
Serum IgE
Animals were bled and serum isolated for total IgE
levels. Serum was also analyzed for zinc levels using the
QuantiChrom Zinc Assay kit (BioAssay Systems, Hay-
ward, CA).
Cytokine production
Liberase/DNase I digests of the lung were prepared to
obtain single lung cell suspensions. Single cell suspen-
sions (2.5 × 105) were incubated for 72 hours in culture
medium (RPMI) or in RPMI treated with Conconavalin
A (10 μg/ml) and supernatants were analyzed by ELISA
for cytokine expression as previously described [12].
Statistical analysis
When applicable, statistical significance was assessed by
one-way analysis of variance (ANOVA). Differences
identified by ANOVA were pinpointed by Student-New-
man-Keuls’ multiple range test.
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Results
Zinc supplementation reduced GC frass-induced airway
inflammation
We previously showed that a single intratracheal inhala-
tion of GC frass to naïve BALB/c mice induced a signifi-
cant immune response within 18 hours [13]. To
determine if zinc supplementation could alter this
response, we performed an i.p. injection of increasing
doses of zinc gluconate (0.1-10 mg/kg) for 3 days prior
to a single intratracheal instillation of GC frass (Figure
1A). As expected, a single exposure to GC frass induced
neutrophil infiltration into the BAL fluid (Figure 2A)
and increased the inflammatory mediator TNFa (Figure
2B). Importantly, administration of zinc gluconate
resulted in decreased neutrophil infiltration into the air-
ways of mice with a concentration of 1 mg/kg, while
TNFa secretion was significantly decreased with a dose
of 0.1 mg/kg zinc gluconate. Next, we wanted to deter-
mine if zinc altered NF-B activation. To do this, we
pretreated mice with zinc gluconate (1 mg/kg) i.p. for 3
days prior to inhalation of GC frass (Figure 1A). 18 h
later, lungs were isolated and nuclear extracts were iso-
lated. We confirmed that GC frass increased NF-B-
DNA binding as determined by electrophoretic mobility
shift assay (EMSA) in whole lung (Figure 3). Pretreat-
ment with zinc gluconate significantly decreased the
level of NF-B-DNA binding. The specificity of NF-B
was shown by the competition of the radiolabeled band
with excess non-labeled NF-B oligonucleotide and the
lack of competition using the non-specific non-labeled
AP-1 oligonucleotide. These data confirm that zinc glu-
conate supplementation can attenuate the inflammatory
response by altering NF-B activation in vivo.
Zinc directly affects neutrophil cytokine production via
NF-B
Using the neutrophil as a marker of an early innate
immune response, we asked whether zinc supplementa-
tion would attenuate an inflammatory response in neu-
trophils. To do this, we isolated bone marrow-derived
neutrophils from naïve wild type mice and treated the
cells ex vivo with GC frass. We found that GC frass sig-
nificantly increased TNFa production from bone mar-
row-derived neutrophils (Figure 4A). Treatment with
zinc gluconate (1 μM) in the presence of the zinc iono-
phore pyrithione (10 μM) significantly reduced GC
frass-induced TNFa production. Due to the difficulties
involved in obtaining primary neutrophils, we decided
to perform additional experiments using HL-60 cells (a
human promyelocytic leukemia cell line that becomes
neutrophil-like following differentiation with DMSO).
GC frass-induced TNFa production in differentiated
HL-60 cells was completely abolished in the presence of
zinc gluconate/pyrithione (Figure 4B). Since GC frass
contains endotoxin [13], an agonist of TLR4, we were
also interested in determining if zinc supplementation
could alter LPS-induced activation of neutrophils. We
confirmed that addition of zinc gluconate was sufficient
to completely attenuate LPS-induced cytokine expres-
sion (Figure 4B). It is important to note that neither
zinc gluconate nor pyrithione, either alone or in
Figure 2 Zinc gluconate decreased airway inflammation in vivo.
Naïve BALB/c mice were given an i.p. injection of PBS or zinc
gluconate (0.1, 1, or 10 mg/kg) once a day for 3 days prior to a
single i.t. inhalation of GC frass (40 μg/40 μl). 18 h later, BAL fluid
was harvested, infiltrated cells counted and BAL fluid was analyzed
by ELISA. In all cases means ± SEM are shown (n = 6 mice per
group). A. Total cells in BAL fluid (different from PBS *p < 0.001;
different from GC frass treated **p < 0.05). B. TNFa ELISA (different
from PBS * < 0.001; different from GC frass treated without zinc
supplementation **p < 0.05, as determined by ANOVA).
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combination, resulted in cell death as measured by LDH
release (data not shown).
To explore the mechanism by which zinc gluconate
regulated TNFa production, we asked whether zinc glu-
conate could inhibit NF-B activation and DNA bind-
ing. HL-60 cells were differentiated in DMSO for 3 days
prior to treatment with GC frass or LPS in the absence
or presence of zinc gluconate and pyrithione. As
expected, both GC frass and LPS increased NF-B-DNA
binding (Figure 4C). Importantly, NF-B-DNA binding
was completely attenuated with zinc supplementation.
Next, we performed a time course of GC frass and LPS
treatment in the absence and presence of zinc supple-
mentation and determined the levels of IBa. We found
increased degradation of IBa following treatment with
both GC frass and LPS (data not shown). Zinc supple-
mentation resulted in the sustained presence of IBa,
suggesting less degradation of the protein. Since IBa
phosphorylation and thus degradation is mediated by
IKK activation, we asked whether zinc gluconate regu-
lated IKK activity as determined by an in vitro kinase
assay. GC frass-induced activation of IKK was attenu-
ated in the presence of zinc gluconate (Figure 4D).
Together these data suggest a role for zinc gluconate
inhibition of NF-B upstream of IKK activation.
Regulation of A20 by zinc gluconate
Given that A20, a seven-zinc finger protein is known to
inhibit NF-B activation, and zinc tempers inflammation,
Figure 3 Zinc supplementation decreased NF-B-DNA binding
in whole lung. Mice were given daily i.p. injections of PBS or zinc
gluconate (10 mg/kg) for 3 days prior to a single i.t. inhalation of
PBS or GC frass (40 μg/40 μl). 4 h later, whole lungs were removed
and snap frozen. Lungs were homogenized, nuclear extracts isolated
and analyzed by EMSA. NF-B-DNA binding is shown, top arrows
designate supershift of p65 and p50. Data shown are representative
from a single mouse (n = 3 mice per group).
Figure 4 Zinc supplementation decreased neutrophil-derived
cytokine production via decreased NF-B activation. A. Bone
marrow-derived neutrophils were isolated and treated with GC frass
(1 μg/ml) or LPS (1 μg/ml) with or without zinc gluconate (1 μM)
and pyrithione (10 μM) for 18 h. Supernatants were clarified and
analyzed by ELISA for TNFa production. Data are means ± SEM (n =
3 separate experiments) and statistical differences assessed by
ANOVA (*p < 0.05). B. HL-60 cells were treated as in A and analyzed
by ELISA for TNFa production. Data are expressed as mean ± SEM
for four experiments (*p < 0.001). C. Zinc supplementation
decreased NF-B-DNA binding. HL-60 cells were stimulated with GC
frass or LPS in the presence of zinc and pyrithione for 4 h. Nuclear
extracts were analyzed for NF-B-DNA binding by EMSA. D. Zinc
supplementation decreased IKK activity. HL-60 cells were cultured
with or without zinc gluconate and pyrithione prior to treatment
with GC frass for 1 h. IKK activation was assessed by in vitro kinase
assay using recombinant IBa as a substrate. PBS treated (P) and
GC frass treated (F) cells cultured with and without zinc.
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we sought to determine if zinc affects A20 protein levels.
We treated differentiated HL-60 cells with GC frass in
the presence or absence of zinc gluconate and/or pyr-
ithione and harvested cells 18 h later. We found an upre-
gulation of A20 protein levels following GC frass
treatment, which was significantly decreased when zinc/
pyrithione were also present (Figure 5A). These results
were somewhat expected since we have shown that zinc
supplementation resulted in decreased NF-B activation
(refer to Figure 3C) and A20 is a downstream gene pro-
duct of NF-B. These data also confirm that pyrithione
alone did not alter A20 protein levels. We next deter-
mined the stability of A20 protein levels shortly following
zinc treatment. To do this, we treated cells with GC frass,
zinc and pyrithione and harvested cell lysate at 2 and 4
hours following treatment. We found that zinc did not
alter A20 protein levels rapidly following treatment (Fig-
ure 5B), suggesting that the decrease in A20 seen at 18 h
was most likely due to transcriptional regulation.
Zinc alters the activity of A20
We considered the possibility that zinc gluconate could
alter A20 activity to potentially make it more efficient.
Since it is known that A20 alters ubiquitination patterns
of RIP1 leading to its degradation, we investigated RIP1
protein levels following zinc treatment. To do this, we
treated DMSO-differentiated HL-60 cells with GC frass
in the presence or absence of zinc and pyrithione and
harvested the cells 30 min to 4 h later. Importantly, we
found that zinc supplementation resulted in decreased
levels of RIP1 following GC frass treatment (Figure 6).
In addition, we investigated the levels of TRAF6,
another downstream target of A20. We found no
changes in the protein levels of TRAF6 following zinc
treatment. Together, this data indicates that the addition
of zinc resulted in decreased RIP1 protein levels, pre-
sumably by altering the ubiquitination state of RIP1
thus causing its degradation. TRAF6 levels remained
unaltered; however it is unclear as to whether A20
altered the levels of ubiquitin on TRAF6, or if the ubi-
quitination state of TRAF6 does not play a role in its
degradation.
Zinc supplementation decreased allergic airway
inflammation in mice
Our data indicate that zinc supplementation results in
decreased inflammation due to decreased NF-B activ-
ity. We were very interested in determining if zinc sup-
plementation could alter experimentally-induced allergic
airway inflammation in our established mouse model.
To do this, we first induced an airway response by sen-
sitizing and challenging mice to GC frass on days 0, 7,
and 14. We have previously shown this method to
induce significant airway hyperresponsiveness to acetyl-
choline, increased serum IgE, increased eosinophilia and
increased Th2 (IL-4, IL-5 and IL-13) cytokine expression
[16,17]. We then administered zinc gluconate or PBS i.p.
to mice on days 14, 15, and 16. On day 17, mice were
analyzed for allergic airway inflammation (refer to Fig-
ure 1B). Serum zinc levels rose in the zinc gluconate-
treated mice from a baseline of 9.05 ± 0.6 μM to 11.8 ±
0.5 μM (n = 12; p = 0.002). As expected, sensitization
and challenge to GC frass resulted in increased airway
responsiveness to cholinergic agent (Figure 7A),
increased serum IgE levels (Figure 7B), and increased
Th2 cytokine expression (Figure 7C and 7D). Interest-
ingly, the addition of zinc gluconate into the i.p. cavity
of mice following sensitization and challenge was able to
significantly decrease airway hyperresponsiveness and
serum IgE levels. There was no significant effect of zinc
gluconate on the Th2 cytokines IL-13 or IL-5 or IL-4
(data not shown). In addition, administration of zinc
gluconate following allergen sensitization and challenge
resulted in decreased airway eosinophil numbers (3315
± 519 cells following allergen challenge compared to
2593 ± 587 cells with zinc supplementation), although
these levels did not reach statistical significance. In our
Figure 5 A20 protein levels following GC frass with or without
zinc supplementation. HL-60 cells were treated with GC frass (1
μg/ml) or LPS (1 μg/ml) with or without zinc gluconate (1 μM) and
pyrithione (10 μM) for 18 h (A) or for either 2 or 4 h (B). Cell lysates
were harvested, separated by gel electrophoresis and probed with
an antibody against A20 or b-actin. Each experiment was performed
3 times.
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asthma model, airway neutrophilia is also present fol-
lowing allergen sensitization and challenge (2639 ± 813)
and was decreased following administration of zinc glu-
conate (1094 ± 268; n = 6 mice per group; p < 0.05).
Together these data suggest that supplementation with
high doses of zinc gluconate alters some aspects of
experimentally-induced allergic airway inflammation in
a mouse model.
Discussion
In this report, we describe a role for zinc supplementa-
tion in modulating the innate immune response to a
common allergen in vivo which is characterized by cel-
lular infiltration and cytokine release into the airways of
mice. In addition, we found that zinc supplementation is
sufficient to decrease airway hyperresponsiveness and
serum IgE levels suggesting an important therapeutic
Figure 7 Zinc supplementation decreased experimentally-induced allergic asthma in mice. BALB/c mice were sensitized on days 0, 7, and
14 with an intratracheal inhalation of PBS or GC frass (40 μg/40 μl). On day 14, 15, and 16 selected mice were administered i.p. injections of zinc
gluconate (10 mg/kg) or PBS. On day 17, mice were anesthetized and acetylcholine was injected after establishment of a stable airway pressure.
Blood was collected and BAL fluid was harvested. Lungs were isolated, and cultured for 3 days in the presence of ConA for cytokine analysis by
ELISA. In all cases, means ± SEM (n = 6 mice per group) were reported and statistical significance was determined by one-way ANOVA. A. AHR
was measured as airway pressure time index (APTI) in cm-H2O × sec -1 (compared to PBS *p > 0.001; compared to GC frass **p = 0.034). B.
Serum IgE levels (compared to PBS *p > 0.001; compared to GC frass **p > 0.001). C. IL-13 levels (compared to PBS; *p > 0.001). D. IL-5 levels
(compared to PBS; *p > 0.001).
Figure 6 RIP1 and TRAF6 protein levels following GC frass with or without zinc supplementation. HL-60 cells were treated with GC frass
(1 μg/ml) or LPS (1 μg/ml) with or without zinc gluconate (1 μM) and pyrithione (10 μM) for times as indicated (0-4 hr). Cell lysates were
harvested, separated by gel electrophoresis and probed with antibodies against RIP1, TRAF6 or b-actin. This experiment was performed 3 times.
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treatment. Our data suggests that zinc works to temper
inflammation at the level of A20 within the NF-B path-
way. A20 is a zinc-fingered protein that is a well-known
inhibitor of the NF-B pathway and was thus a good
potential target for the location of zinc’s anti-inflamma-
tory effect within this pathway. In our study, we found
that zinc supplementation, when added concurrently
with GC frass, did not affect A20 levels in the short
term (4 h), but resulted in decreased A20 protein levels
at 18 h. We postulate that this was most likely due to
transcriptional regulation with the enhancement of the
NF-B negative feedback loop and inhibition of contin-
ued activation of NF-B, thus eventually decreasing A20
protein production. It has been shown that zinc can
induce increased A20 levels in the presence of a variety
of stimuli including LPS [18] and phorbol myristate
acetate (PMA) [19]. These experiments differed from
ours in that media containing zinc was added to cells
for 10 days prior to stimulation, but they support our
interpretation that zinc regulates A20 to alter NF-B
activity.
Our results indicate a potential mechanism by which
zinc regulates NF-B activity; i.e. by enhancing the
activity of A20 thus resulting in de-ubiquitination of
RIP1 and leading to its degradation. The ubiquitin edit-
ing abilities of A20 were recently examined and better
defined. Shembade et. al. [5] showed that A20 removes
the activating chains of ubiquitin from locus K63 on
RIP1 and facilitates the addition of inhibitory chains to
locus K48, targeting RIP1 for degradation and thus pre-
venting the activation of IKK downstream. They also
showed that A20 inhibits the polyubiquitinization and
activation of TRAF6, a process that is dependent on
Ubc13 enzymatic activity. Ubc13 is also ubiquitinated at
K48 by A20 and targeted for degradation, but this
occurs late after stimulation. TRAF6 is then rendered
inactive, though not degraded [5]. Utilizing these find-
ings, we were able to evaluate A20 activity using RIP1
and TRAF6 protein levels as a surrogate. With respect
to A20 activity, we were able to show that RIP1 was
degraded more quickly in the presence of zinc gluconate
after stimulation with GC frass, but TRAF6 levels
remained unchanged. These findings suggest that the
addition of zinc gluconate augments the activity of A20;
enabling it to act more rapidly on RIP1 resulting in its
degradation and thus ceasing the NF-B inflammatory
cascade more quickly. A limitation of the current study
was our evaluation of A20 activity via RIP1 as an indir-
ect assessment; however our studies clearly show that in
the presence of zinc, RIP1 degradation is enhanced, sug-
gesting an increased proteosomal targeting due to
altered ubiquitin states. Our findings suggest that zinc is
acting on the NF-B pathway at the level of A20 to
further enhance its inhibitory effects.
In this study we also wanted to investigate zinc as an
anti-inflammatory with potential therapeutic utility for
airway inflammation. Asthma is a chronic inflammatory
disease of the airways and is characterized by increased
mucus production and airway hyperresponsiveness. Sev-
eral studies have shown a role for increased NF-B in
asthmatics, including increased NF-B p65 protein
abundance, IBa phosphorylation and IKK activity in
peripheral blood mononuclear cells (PBMC) of uncon-
trolled asthmatics compared to normal individuals [20]
and greater levels of NF-B p65 and p50 activation in
cultured bronchial epithelial cells from untreated asth-
matics than controls [21]. NF-B was also found to be
upregulated in bronchial epithelial cells a murine model
of ovalbumin-induced allergic airway inflammation [22].
The importance of NF-B signaling in allergic inflam-
mation and mucus production was shown using mice
with IKK-deficient Clara epithelial cells [23]. In this
study, we found a significant reduction in airway hyper-
responsiveness in our murine model by administering
zinc gluconate for three days following the final allergen
exposure. Importantly, the levels of serum IgE were sub-
stantially decreased following zinc administration. IgE is
known to bind to specific Fcε receptors on mast cells
thus result in release of histamine and other inflamma-
tory substances to produce an allergic cascade. Zinc
supplementation did not appear to have any effect on
levels of the Th2 cytokines IL-13, IL-5 and IL-4. Much
of the literature on zinc and asthma has focused primar-
ily on levels of dietary zinc; however Lang et. al. [24]
recently showed that zinc supplementation following
establishment of allergic inflammation reduced the levels
of eosinophils and lymphocytes in the BAL fluid of
mice. They failed to find a significant difference in the
amount of mucus hyperplasia, determined by PAS stain-
ing, following zinc administration however. We also
found decreased numbers of eosinophils and neutrophils
in the BAL fluid of mice; however unlike neutrophil
levels, the decrease in eosinophil levels did not reach
statistical significance. It is possible that the amount of
times zinc is administered (i.e. 3 times in our protocol
compared to twice a week from days 34-52 in the Lang
protocol) was responsible for the different results. To
our knowledge, this is the first report showing that zinc
supplementation can modulate airway responsiveness to
cholinergic agents.
The literature on zinc as a potent antioxidant is vast
but what role this may have in airway inflammation
remains unclear. Recent studies have looked at abnor-
mal distributions of trace minerals, including zinc, as an
instigator of oxidative damage and inflammation in
asthma [25,26]. Prasad et. al. [18] investigated the role
of zinc as an antioxidant and after supplementation to
human subjects, noted a decrease in oxidative stress and
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NF-B activation in isolated mononuclear cells when
compared to placebo. TNFa and IL-1b are inflammatory
cytokines known to exert oxidative stress on cells via the
generation of reactive oxygen species (ROS). In their
study, they also noted a decrease in TNFa and IL-1b
cytokine levels in their volunteers who took zinc supple-
ments, suggesting that one way in which zinc functions
as an antioxidant is by negatively regulating the gene
expression of these inflammatory cytokines to prevent
the formation of ROS [18]. Thus, zinc’s role as an anti-
oxidant likely works concurrently with its anti-inflam-
matory role via similar or overlapping biochemical
mechanisms. Similar to Prasad et. al., we were able to
show that zinc negatively inhibits NF-B-induced cyto-
kine production. We acknowledge that some of the
positive effects noted on airway hyperresponsivity and
inflammation may have been an antioxidant effect of
zinc supplementation. However, we continue to promote
the supplementation of zinc as a therapeutic to temper
the inflammation as well as the oxidative stress induced
by allergic stimuli in the airways.
Conclusion
Zinc gluconate is an inexpensive medication, readily
available and administered both parenterally and orally.
With the severity and prevalence of asthma on the rise,
our data suggest the possibility of a readily available,
easily dosed, and cost effective manner to aid in the
suppression of airway hyperresponsiveness.
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